TH Theratechnologies Inc.

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies Reports on its Annual Meeting of Shareholders

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.

Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and appointed KPMG LLP as the Company’s auditors for the current fiscal year. All candidates proposed for the position of director were elected in the following proportion:

 FOR

% FORABSTENTION

% ABSTENTION
Joseph Arena22,405,047 93.09%1,663,754 6.91%
Frank Holler21,008,601 87.29%3,060,200 12.71%
Paul Lévesque20,966,427 87.11%3,102,374 12.89%
Andrew Molson21,067,050 87.53%3,001,751 12.47%
Dawn Svoronos20,964,213 87.10%3,104,588 2.90%
Elina Tea21,734,254 90.30%2,334,547 9.70%
Dale Weil21,009,681 87.29%3,059,120 12.71%
Jordan Zwick23,107,383 96.01%961,418 3.99%

Frank Holler will now act as Chair of the Board of Directors of the Company.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at , on SEDAR+ at  and on EDGAR at . Follow Theratechnologies on  and  (formerly Twitter).

Contacts:

Investor inquiries:

Philippe Dubuc

Senior Vice President and Chief Financial Officer



1-438-315-6608

Media inquiries:

Julie Schneiderman

Senior Director, Communications & Corporate Affairs



1-514-336-7800



EN
09/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies Reports on its Annual Meeting of Shareholders MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and appointed KPMG LLP as the Company’s auditors for the current fiscal year. All ...

 PRESS RELEASE

Theratechnologies rend compte de son assemblée annuelle des actionnair...

Theratechnologies rend compte de son assemblée annuelle des actionnaires MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation de traitements innovateurs, a rapporté les résultats du vote lors de son assemblée annuelle des actionnaires qui a eu lieu aujourd’hui en mode virtuel uniquement. Les actionnaires ont voté pour les divers candidats mentionnés ci-dessous en vue de leur élection au conseil d’administration de la S...

 PRESS RELEASE

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacoki...

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today ann...

 PRESS RELEASE

Theratechnologies présentera des données à long terme sur l’efficacité...

Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO Dévoilement de données à long terme des parties 1 et 2 de l’essai clinique de phase I portant sur le sudocétaxel zendusortide dans les tumeurs solidesLa partie 3 de la phase I de l’essai sur le cancer de l’ovaire avancé se poursuit MONTRÉAL, 02 mai 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entre...

 PRESS RELEASE

Theratechnologies Announces Mailing of Management Proxy Circular in Co...

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024 management proxy circular to shareholders in connection with its virtual annual meeting of shareholders to be held on May 9, 2024, at 10:00 a.m. ET. Shareholders are encouraged to vote ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch